ALKA-SELTZER

This brand name is authorized in Austria, Canada, Estonia, France, Germany, Hong Kong SAR China, Ireland, Malta, Mexico, Romania, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug ALKA-SELTZER contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII R16CO5Y76E - ASPIRIN
 

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs.

 
Read more about Acetylsalicylic acid
2
UNII 8MDF5V39QO - SODIUM BICARBONATE
 

Sodium bicarbonate has antacid properties. Sodium bicarbonate causes neutralisation of gastric acid with the production of carbon dioxide.

 
Read more about Sodium bicarbonate
3
UNII 2968PHW8QP - CITRIC ACID MONOHYDRATE
 

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate.

 
Read more about Citric acid

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 ALKA-SELTZER Effervescent tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
N02BA01 Acetylsalicylic acid N Nervous system → N02 Analgesics → N02B Other analgesics and antipyretics → N02BA Salicylic acid and derivatives
Discover more medicines within N02BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
CA Health Products and Food Branch 02152746, 02245367
DE Bundesinstitut für Arzneimittel und Medizinprodukte 04153611
EE Ravimiamet 1003644
FR Base de données publique des médicaments 66725120
GB Medicines & Healthcare Products Regulatory Agency 49258, 49259
HK Department of Health Drug Office 44990
MT Medicines Authority MA639/00901
MX Comisión Federal para la Protección contra Riesgos Sanitarios 17518
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W51368003
SG Health Sciences Authority 08632P
TR İlaç ve Tıbbi Cihaz Kurumu 8699546070879
ZA Health Products Regulatory Authority 31/2.8/0628

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.